Literature DB >> 35189717

Botulinum Toxin A for the Treatment of Sympathomimetic Pressor-Induced Digital Hand Ischemia in the Critically Ill Intensive Care Unit Patient.

Henning De May1, Avra S Laarakker1, Gregory Borah1.   

Abstract

Vasopressor-induced ischemia of the hand, while relatively rare, is a severe complication in critically ill intensive care unit (ICU) patients requiring high concentrations of sympathomimetic pressors and often results in digit necrosis and amputation. Currently, there are no widely accepted approaches for treating this cause of peripheral digital ischemia. Case reports have demonstrated that reducing the concentration of vasopressors that patients are given may reverse the progression of ischemic events prior to necrosis. While this approach is at odds with the principle of "life over limb," it demonstrates that digit necrosis can be reversed, resulting in improved outcomes. Here, we present a therapeutic strategy for treating digital limb ischemia in the septic ICU patient without the need to lower systemic vasopressor dose by using locally injected botulinum toxin A into ischemic hands.

Entities:  

Keywords:  anatomy; botox; diagnosis; digits; outcomes; rehabilitation; research and health outcomes; specialty; treatment; vascular

Mesh:

Substances:

Year:  2022        PMID: 35189717      PMCID: PMC9465786          DOI: 10.1177/15589447221075666

Source DB:  PubMed          Journal:  Hand (N Y)        ISSN: 1558-9447


  14 in total

1.  Botulinum toxin in the treatment of Raynaud's phenomenon: a pilot study.

Authors:  T Sycha; M Graninger; E Auff; P Schnider
Journal:  Eur J Clin Invest       Date:  2004-04       Impact factor: 4.686

Review 2.  Researching bladder afferents-determining the effects of β(3) -adrenergic receptor agonists and botulinum toxin type-A.

Authors:  Anthony Kanai; Jean-Jacques Wyndaele; Karl-Erik Andersson; Christopher Fry; Youko Ikeda; Irina Zabbarova; Stefan De Wachter
Journal:  Neurourol Urodyn       Date:  2011-06       Impact factor: 2.696

Review 3.  The role of botulinum toxin in vasospastic disorders of the hand.

Authors:  Michael W Neumeister
Journal:  Hand Clin       Date:  2014-11-25       Impact factor: 1.907

Review 4.  Role of botulinum neurotoxin-A in cerebral revascularization graft vasospasm prevention: current state of knowledge.

Authors:  Kristine Ravina; Ben A Strickland; Robert C Rennert; Joseph N Carey; Jonathan J Russin
Journal:  Neurosurg Focus       Date:  2019-02-01       Impact factor: 4.047

5.  The effect of botulinum neurotoxin-A on blood flow in rats: a potential mechanism for treatment of Raynaud phenomenon.

Authors:  Austin V Stone; L Andrew Koman; Michael F Callahan; Delrae M Eckman; Beth P Smith; Johannes F Plate; Thomas L Smith
Journal:  J Hand Surg Am       Date:  2012-03-03       Impact factor: 2.230

Review 6.  Botulinum Toxin for the Treatment of Intractable Raynaud Phenomenon.

Authors:  Jose E Gallegos; Dani C Inglesby; Zachary T Young; Fernando A Herrera
Journal:  J Hand Surg Am       Date:  2020-09-16       Impact factor: 2.230

7.  Botulinum Toxin A Salvage of Ischemic Hand Trauma.

Authors:  Avra S Laarakker; Gregory Borah
Journal:  Plast Reconstr Surg       Date:  2020-01       Impact factor: 4.730

Review 8.  Botulinum toxin for the treatment of strabismus.

Authors:  Fiona J Rowe; Carmel P Noonan
Journal:  Cochrane Database Syst Rev       Date:  2017-03-02

9.  Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine.

Authors:  Clare P Herd; Claire L Tomlinson; Caroline Rick; William J Scotton; Julie Edwards; Natalie J Ives; Carl E Clarke; A J Sinclair
Journal:  BMJ Open       Date:  2019-07-16       Impact factor: 2.692

Review 10.  Long-term efficacy and safety of botulinum toxin injections in dystonia.

Authors:  Juan Ramirez-Castaneda; Joseph Jankovic
Journal:  Toxins (Basel)       Date:  2013-02-04       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.